Inventor
HARRIS ROY L
US16 patents
⚠️ This page may combine multiple inventors who share the name “HARRIS ROY L”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
SIGNAL PHARM LLC
7 patentsUS9771371B2Sep 26, 2017
Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors
SIGNAL PHARM LLC4 citations83
US8907087B2Dec 9, 2014
Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors
SIGNAL PHARM LLC4 citations83
US9079900B2Jul 14, 2015
Methods of synthesis and purification of heteroaryl compounds
SIGNAL PHARM LLC5 citations82
US10167290B2Jan 1, 2019
Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors
SIGNAL PHARM LLC1 citations72
US11292796B2Apr 5, 2022
Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors
SIGNAL PHARM LLC0 citations62
US10683298B2Jun 16, 2020
Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors
SIGNAL PHARM LLC0 citations51
US9193692B2Nov 24, 2015
Halogen substituted pyrazines as intermediates of mTOR kinase inhibitors
SIGNAL PHARM LLC0 citations51
PERRIN-NINKOVIC SOPHIE
3 patentsUS8492381B2Jul 23, 2013
Pyrazino[2,3-b]pyrazine mTOR kinase inhibitor for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
PERRIN-NINKOVIC SOPHIE44 citations95
US8110578B2Feb 7, 2012
Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
PERRIN-NINKOVIC SOPHIE67 citations95
US8507492B2Aug 13, 2013
Pyrazino[2,3-b]pyrazine mTOR kinase inhibitor for oncology indications and diseases associated with the mTOR/PI3K/AKT pathway
PERRIN-NINKOVIC SOPHIE22 citations90
SIGNAL PHARMACEUTICAL LLC
3 patentsUS9428509B2Aug 30, 2016
Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
SIGNAL PHARMACEUTICAL LLC6 citations81
US9346812B2May 24, 2016
Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
SIGNAL PHARMACEUTICAL LLC6 citations81
US9795607B2Oct 24, 2017
Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
SIGNAL PHARMACEUTICAL LLC0 citations49
CELGENE CORP
2 patentsUS11945804B2Apr 2, 2024
Substituted 4-aminoisoindoline-1,3-dione compounds, compositions thereof, and methods of treatment therewith
CELGENE CORP0 citations61
US11358952B2Jun 14, 2022
Substituted 4-aminoisoindoline-1,3-dione compounds, compositions thereof, and methods of treatment therewith
CELGENE CORP1 citations60